RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer

Cancer Medicine

Volumn 1, Issue 1, 2012, Pages 68-75

  Sasaki, Hidefumi ^a   Shimizu, Shigeki ^b   Tani, Yoichi ^c   Maekawa, Masahiko ^d   Okuda, Katsuhiro ^a   Yokota, Keisuke ^a   Shitara, Masayuki ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c Dako Japan Inc   (Japan)

^d GSP Lab Inc   (Japan)

Author keywords

FISH; KIF5B RET; Lung cancer; RET expression

Indexed keywords

BETA ACTIN; MESSENGER RNA; PROTEIN RET;

AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE EXPRESSION; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RET GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING;

EID: 84880681062     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.13     Document Type: Article

References (26)

1. Ginsberg, R. J., K. Kris, and G. Armstrong. 1993. Cancer of the lung. Pp. 673-682 in V. T. De Vita Jr and S. Hellman, eds. Principles and practice of oncology. 4th ed. Lippincott, Philadelphia.
2. Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
3. Lynch, T. J., D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139.
4. Sasaki, H., K. Endo, A. Konishi, M. Takada, M. Kawahara, K. Iuchi, et al. 2005. EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin. Cancer Res. 11:2924-2929.
5. Sasaki, H., S. Shimizu, K. Endo, M. Takada, M. Kawahara, H. Tanaka, et al. 2006. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int. J. Cancer 118:180-184.
6. Fukuoka, M., Y.-L. Wu, S. Thongprasert, P. Sunpaweravong, S. S. Leong, V. Sriuranpong, et al. 2011. Biomarker analyses and first overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29:2866-2874.
7. Soda, H., Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, et al. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566.
8. Ju, Y. S., W. C. Lee, J. Y. Shin, S. Lee, T. Bleazard, J. K. Won, et al. 2012. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed whole-genome and transcriptome sequencing. Genome Res. 22:436-445.
9. Lipson, D., M. Capelletti, R. Yelensky, G. Otto, A. Parker, M. Jarosz, et al. 2012. Massively parallel sequencing assay identifies novel ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18:382-384.
10. Kwak, E. L., Y. L. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancers. N. Engl. J. Med. 363:1692-1703.
11. Takeuchi, K., Y. L. Choi, M. Soda, K. Inamura, Y. Togashi, S. Hatano, et al. 2008. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res. 14:6618-6624.
12. Solomon, B., M. Varella-Garcia, and D. R. Camidge. 2009. ALK gene rearrangements: a new therapeutic target in a molecularly-defined subset of non-small cell lung cancer. J. Thorac. Oncol. 4:1450-1454.
13. Shaw, A. T., B. Y. Yeap, M. Mino-Kenudson, B. R. Digumarthy, B. R. Costa, R. S. Heist, et al. 2009. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27:4247-4253.
14. Ou, S. H., L. Bezhenova, D. R. Camidge, B. J. Solomon, J. Herman, T. Kain, et al. 2010. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (Crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J. Thorac. Oncol. 5:2044-2046.
15. Takeuchi, K., Y. L. Choi, Y. Togashi, M. Soda, S. Hatano, K. Inamura, et al. 2009. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15:3143-3149.
16. Henderson, Y. C., S. H. Ahn, Y. Kang, and G. L. Clayman. 2008. Sorafenib potently inhibits papillary thyroid carcinomas haboring RET/PTC1 rearrangement. Clin. Cancer Res. 14:4908-4914.
17. Carlomagno, F., S. Anaganti, T. Guida, G. Salvatore, G. Trancone, S. M. Wilhelm, et al. 2006. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98:326-334.
18. Kim, D. W., Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, et al. 2006. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 91:4070-4076.
19. Dawson, S., N. M. Conus, G. C. Toner, J. M. Raleigh, R. J. Hicks, G. McArthur, et al. 2008. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 19:547-552.
20. Kohno, T., H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, T. Nammo, et al. 2012. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 18:375-377.
21. Takeuchi, K., M. Soda, Y. Togashi, R. Suzuki, S. Sakata, S. Hatano, et al. 2012. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18:378-381.
22. Wolff, A. C., M. E. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, et al. 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25:118-145.
23. Paik, J. H., G. Choe, H. Kim, J. Y. Choe, H. J. Lee, C. T. Lee, et al. 2011. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer correlation with fluorescence in situ hybridization. J. Thorac. Oncol. 6:466-472.
24. Yang, P., K. Kulig, J. M. Boland, M. R. Erickson-Johnson, A. M. Oliveira, J. Wampfler, et al. 2012. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J. Thorac. Oncol. 7:90-97.
25. Yi, E. S., J. M. Boland, J. J. Maleszewski, A. C. Roden, A. M. Oliveira, M. C. Aubry, et al. 2011. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J. Thorac. Oncol. 6:459-465.
26. Mino-Kenudson, M., L. R. Chirieac, K. Law, J. L. Hornick, N. Lindeman, E. J. Mark, et al. 2010. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 16:1561-1571.